Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-FLVC-001 for PCARP
NCT06565572Phase 1Enrolling by invitation
- Sponsor
- University of Colorado Denver
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nL-FLVC-001 in posterior column ataxia with retinitis pigmentosa (PCARP), sponsored by University of Colorado Denver. Primary endpoints: Number of participants with treatment-related adverse events at 12 months, Visual acuity at 12 months and 2 more. Started Aug 2023; status: enrolling by invitation.
02
Drugs
nL-FLVC-001
03
Conditions
posterior column ataxia with retinitis pigmentosa (PCARP)
Beyond the preview
Go deeper on NCT06565572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565572.